In animal models of C26 cachexia, systemic inflammation is an important factor contributing to cancer cachexia, the main drivers of which are generally IL-6 and leukemia inhibitory factor (LIF).27, 28, 29 In cancer patients with particularly high IL-6 levels, there is a clinical benefit of blocking IL-6 with TocilizuMab.30 The gene discussed is LIF; the disease is cancer.